JP2024522076A - 抗ｃｅａｃａｍ５／６抗原結合分子およびその処置方法 - Google Patents

抗ｃｅａｃａｍ５／６抗原結合分子およびその処置方法 Download PDF

Info

Publication number
JP2024522076A
JP2024522076A JP2023571803A JP2023571803A JP2024522076A JP 2024522076 A JP2024522076 A JP 2024522076A JP 2023571803 A JP2023571803 A JP 2023571803A JP 2023571803 A JP2023571803 A JP 2023571803A JP 2024522076 A JP2024522076 A JP 2024522076A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522076A5 (enExample
Inventor
ファ アンドレ チュー，ブーン
ウィー ゴー，ティン
イー ディン，メイ
ワン レオン，ハウ
ドルフミュラー，ジモーネ
シオン タン，バン
シック リム，チェック
シュトゥンケル，ヴァルター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of JP2024522076A publication Critical patent/JP2024522076A/ja
Publication of JP2024522076A5 publication Critical patent/JP2024522076A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2023571803A 2021-05-21 2022-05-20 抗ｃｅａｃａｍ５／６抗原結合分子およびその処置方法 Pending JP2024522076A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202105379W 2021-05-21
SG10202105379W 2021-05-21
PCT/SG2022/050336 WO2022245299A2 (en) 2021-05-21 2022-05-20 Anti-ceacam5/6 antigen-binding molecules and methods of treatment thereof

Publications (2)

Publication Number Publication Date
JP2024522076A true JP2024522076A (ja) 2024-06-11
JP2024522076A5 JP2024522076A5 (enExample) 2025-05-27

Family

ID=84141986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571803A Pending JP2024522076A (ja) 2021-05-21 2022-05-20 抗ｃｅａｃａｍ５／６抗原結合分子およびその処置方法

Country Status (9)

Country Link
US (1) US20240238433A1 (enExample)
EP (1) EP4341295A4 (enExample)
JP (1) JP2024522076A (enExample)
KR (1) KR20240012458A (enExample)
CN (1) CN117957252A (enExample)
AU (1) AU2022277056A1 (enExample)
BR (1) BR112023024141A2 (enExample)
CA (1) CA3218876A1 (enExample)
WO (1) WO2022245299A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025114426A1 (en) 2023-11-28 2025-06-05 Universite De Strasbourg Preparation of protein conjugates via one-pot multicomponent reaction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
JP2018502918A (ja) * 2015-01-09 2018-02-01 アデュロ バイオテック ホールディングス ヨーロッパ ベスローテン フエンノートシャップ 改変されたａｐｒｉｌ結合抗体
JP2019521649A (ja) * 2016-05-02 2019-08-08 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JP2019522960A (ja) * 2016-04-21 2019-08-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
JP2020510631A (ja) * 2016-10-10 2020-04-09 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 抗ｃｅａｃａｍ６抗体及び使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
JP2018502918A (ja) * 2015-01-09 2018-02-01 アデュロ バイオテック ホールディングス ヨーロッパ ベスローテン フエンノートシャップ 改変されたａｐｒｉｌ結合抗体
JP2019522960A (ja) * 2016-04-21 2019-08-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
JP2019521649A (ja) * 2016-05-02 2019-08-08 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JP2020510631A (ja) * 2016-10-10 2020-04-09 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 抗ｃｅａｃａｍ６抗体及び使用方法

Also Published As

Publication number Publication date
CA3218876A1 (en) 2022-11-24
AU2022277056A1 (en) 2023-12-21
US20240238433A1 (en) 2024-07-18
KR20240012458A (ko) 2024-01-29
CN117957252A (zh) 2024-04-30
AU2022277056A9 (en) 2024-01-25
WO2022245299A3 (en) 2023-02-02
WO2022245299A2 (en) 2022-11-24
EP4341295A4 (en) 2025-05-07
EP4341295A2 (en) 2024-03-27
BR112023024141A2 (pt) 2024-01-30

Similar Documents

Publication Publication Date Title
JP7776555B2 (ja) 抗ｃｄｈ６抗体及び抗ｃｄｈ６抗体－薬物コンジュゲート
JP6267158B2 (ja) 抗体およびイムノコンジュゲートとこれらの使用方法
JP2020099351A (ja) 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
AU2018282328A1 (en) DLL3 modulators and methods of use
JP2017518040A (ja) 新規の抗ｒｎｆ４３抗体および使用方法
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
JP2025504738A (ja) クローディン１８．２アンタゴニストおよびｐｄ－１／ｐｄ－ｌ１系阻害剤の併用療法
CN103025760A (zh) 人源化egfr抗体
TW202039571A (zh) Muc18特異性抗體
EP4458850A1 (en) Anti-ror1 antibody, and anti-ror1 antibody-drug conjugate and medical uses thereof
JP2023512827A (ja) 抗原結合分子およびその使用
JP7430137B2 (ja) 抗体および使用方法
US20260139049A1 (en) Anti-cldn6 antibodies and use thereof
WO2021247908A1 (en) Trophoblast cell-surface antigen-2 (trop-2) antibodies
KR20240021294A (ko) 항-her3 항체, 이를 함유하는 항체-약물 접합체 및 그 용도
US20240238433A1 (en) Anti-ceacam5/6 antigen-binding molecules and methods of treatment thereof
US20250277060A1 (en) Antigen binding molecules and methods thereof i
US20240132595A1 (en) Antigen binding molecules and methods thereof ii
US20240018221A1 (en) Antigen binding molecules and uses thereof
WO2025207033A1 (en) Anti-trop2 antigen-binding molecules
WO2024046245A1 (zh) 抗pvrig抗体及其应用
CN120209140A (zh) 靶向免疫细胞抗原的抗体及其用途
HK1182721B (en) Antibodies and immunoconjugates and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260731